De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Kobayashi Pharmaceutical Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Satoshi Yamane

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	0.01%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	6yrs

Recente managementupdates

Recent updates

Kobayashi Pharmaceutical's (TSE:4967) Soft Earnings Are Actually Better Than They Appear

Aug 21

Getting In Cheap On Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) Is Unlikely

Aug 04

Investor Optimism Abounds Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) But Growth Is Lacking

Apr 21

Estimating The Fair Value Of Kobayashi Pharmaceutical Co., Ltd. (TSE:4967)

Apr 03

Investors Met With Slowing Returns on Capital At Kobayashi Pharmaceutical (TSE:4967)

Feb 27

CEO

Satoshi Yamane (64 yo)

less than a year

Tenure

Mr. Satoshi Yamane is President of Kobayashi Pharmaceutical Co. Ltd. from July 2024 and serves as Senior MD & Head of Sustainability Management Headquarters since January 2024. He was General Manager of Gr...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Satoshi Yamane	President	18.3yrs	geen gegevens	0.011% ¥ 46.1m
Kunio Ito	Independent Outside Director	11.3yrs	geen gegevens	geen gegevens
Yoshiro Katae	Independent Outside Director	2.6yrs	geen gegevens	geen gegevens
Yoko Hatta	Outside Audit & Supervisory Board Member	9.3yrs	geen gegevens	geen gegevens
Kaori Sasaki	Independent Outside Director	8.3yrs	geen gegevens	geen gegevens
Ikeaki Ariizumi	Independent Outside Director	2.6yrs	geen gegevens	geen gegevens
Takashi Kawanishi	Full-time Audit & Supervisory Board Member	3.6yrs	geen gegevens	geen gegevens
Sumio Moriwaki	Outside Audit & Supervisory Board Member	1.6yrs	geen gegevens	geen gegevens

6.0yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 4967 wordt beschouwd als ervaren (gemiddelde ambtstermijn 6 jaar).

Kobayashi Pharmaceutical Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Kobayashi Pharmaceutical Co., Ltd., Annual General Meeting, Mar 28, 2024

Kobayashi Pharmaceutical Co., Ltd., Annual General Meeting, Mar 30, 2023

Kobayashi Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2021

Recent updates

Consensus EPS estimates fall by 14%

Price target decreased by 8.3% to JP¥5,820

Kobayashi Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Nov 08, 2024

Kobayashi Pharmaceutical's (TSE:4967) Soft Earnings Are Actually Better Than They Appear

Consensus EPS estimates fall by 22%

Getting In Cheap On Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) Is Unlikely

Kobayashi Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Aug 08, 2024

Upcoming dividend of JP¥44.00 per share

Consensus EPS estimates fall by 12%

Price target decreased by 8.0% to JP¥6,348

First quarter 2024 earnings: EPS misses analyst expectations

Price target decreased by 16% to JP¥6,898

Kobayashi Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on May 10, 2024

Investor Optimism Abounds Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) But Growth Is Lacking

New minor risk - Share price stability

Estimating The Fair Value Of Kobayashi Pharmaceutical Co., Ltd. (TSE:4967)

Investor sentiment deteriorates as stock falls 18%

Investors Met With Slowing Returns on Capital At Kobayashi Pharmaceutical (TSE:4967)

Kobayashi Pharmaceutical Co., Ltd., Annual General Meeting, Mar 28, 2024

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Kobayashi Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Feb 09, 2024

Upcoming dividend of JP¥53.00 per share at 1.5% yield

New minor risk - Shareholder dilution

Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) announces an Equity Buyback for 1,924,600 shares, representing 2.53% for ¥11,999.88 million.

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) acquired Focus Consumer Healthcare, LLC.

Second quarter 2023 earnings: EPS exceeds analyst expectations

Upcoming dividend of JP¥39.00 per share at 1.1% yield

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Kobayashi Pharmaceutical Co., Ltd., Annual General Meeting, Mar 30, 2023

Upcoming dividend of JP¥47.00 per share

Kobayashi Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on May 10, 2023

Third quarter 2022 earnings: EPS exceeds analyst expectations

Third quarter 2022 earnings: EPS exceeds analyst expectations

Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) announces an Equity Buyback for 1,265,800 shares, representing 1.64% for ¥9,999.82 million.

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of JP¥38.00 per share

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Upcoming dividend of JP¥44.00 per share

Third quarter 2021 earnings released: EPS JP¥89.58 (vs JP¥90.07 in 3Q 2020)

Second quarter 2021 earnings released: EPS JP¥54.41 (vs JP¥57.27 in 2Q 2020)

Upcoming dividend of JP¥35.00 per share

First quarter 2021 earnings released: EPS JP¥46.42 (vs JP¥47.87 in 1Q 2020)

Full year 2020 earnings released: EPS JP¥246 (vs JP¥244 in FY 2019)

Kobayashi Pharmaceutical Co., Ltd. to Report Q1, 2021 Results on Apr 27, 2021

New 90-day low: JP¥10,460

Kobayashi Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2021

Full year 2020 earnings released: EPS JP¥246 (vs JP¥244 in FY 2019)

Revenue and earnings miss expectations

Kobayashi Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Feb 01, 2021

New 90-day high: JP¥12,880

Upcoming Dividend of JP¥41.00 Per Share

New 90-day high: JP¥12,610

Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) signed an contract to acquire Alva-Amco Pharmacal Companies, Inc. from Trusts all owned by the founder's family for approximately $110 million.

CEO

Tenure

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd